Ultragenyx Net Income
| RARE Stock | USD 20.52 2.98 12.68% |
As of the 15th of February 2026, Ultragenyx has the Coefficient Of Variation of (1,591), variance of 41.99, and Risk Adjusted Performance of (0.04). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Ultragenyx, as well as the relationship between them. Please validate Ultragenyx market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Ultragenyx is priced more or less accurately, providing market reflects its prevalent price of 20.52 per share. Given that Ultragenyx has information ratio of (0.07), we advise you to double-check Ultragenyx's current market performance to make sure the company can sustain itself at a future point.
Ultragenyx Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.9769 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -512.3 M | -486.7 M | |
| Net Loss | -512.3 M | -537.9 M | |
| Net Loss | -636.7 M | -604.8 M | |
| Net Loss | (5.83) | (6.12) | |
| Net Income Per E B T | 1.01 | 0.80 |
Ultragenyx | Net Income | Build AI portfolio with Ultragenyx Stock |
Analyzing Ultragenyx's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Ultragenyx's current valuation and future prospects.
Latest Ultragenyx's Net Income Growth Pattern
Below is the plot of the Net Income of Ultragenyx over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ultragenyx financial statement analysis. It represents the amount of money remaining after all of Ultragenyx operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ultragenyx's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ultragenyx's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (569.18 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ultragenyx Net Income Regression Statistics
| Arithmetic Mean | (297,879,824) | |
| Coefficient Of Variation | (81.08) | |
| Mean Deviation | 209,452,401 | |
| Median | (245,874,000) | |
| Standard Deviation | 241,516,847 | |
| Sample Variance | 58330.4T | |
| Range | 700.6M | |
| R-Value | (0.92) | |
| Mean Square Error | 9484.3T | |
| R-Squared | 0.85 | |
| Slope | (44,031,551) | |
| Total Sum of Squares | 933286.2T |
Ultragenyx Net Income History
Other Fundumenentals of Ultragenyx
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ultragenyx Net Income component correlations
Ultragenyx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ultragenyx is extremely important. It helps to project a fair market value of Ultragenyx Stock properly, considering its historical fundamentals such as Net Income. Since Ultragenyx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ultragenyx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ultragenyx's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Ultragenyx diversify its offerings? Factors like these will boost the valuation of Ultragenyx. Anticipated expansion of Ultragenyx directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ultragenyx data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (5.83) | Revenue Per Share | Quarterly Revenue Growth 0.147 | Return On Assets | Return On Equity |
Understanding Ultragenyx requires distinguishing between market price and book value, where the latter reflects Ultragenyx's accounting equity. The concept of intrinsic value - what Ultragenyx's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ultragenyx's price substantially above or below its fundamental value.
It's important to distinguish between Ultragenyx's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ultragenyx should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Ultragenyx's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Ultragenyx 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ultragenyx's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ultragenyx.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Ultragenyx on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Ultragenyx or generate 0.0% return on investment in Ultragenyx over 90 days. Ultragenyx is related to or competes with Dyne Therapeutics, Centessa Pharmaceuticals, Xenon Pharmaceuticals, Apogee Therapeutics, Ascentage Pharma, Celcuity LLC, and CG Oncology. Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, an... More
Ultragenyx Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ultragenyx's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ultragenyx upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 51.23 | |||
| Value At Risk | (4.30) | |||
| Potential Upside | 7.73 |
Ultragenyx Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ultragenyx's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ultragenyx's standard deviation. In reality, there are many statistical measures that can use Ultragenyx historical prices to predict the future Ultragenyx's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.90) | |||
| Treynor Ratio | (0.27) |
Ultragenyx February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.14 | |||
| Coefficient Of Variation | (1,591) | |||
| Standard Deviation | 6.48 | |||
| Variance | 41.99 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.90) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 51.23 | |||
| Value At Risk | (4.30) | |||
| Potential Upside | 7.73 | |||
| Skewness | (4.02) | |||
| Kurtosis | 27.46 |
Ultragenyx Backtested Returns
Ultragenyx owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0699, which indicates the firm had a -0.0699 % return per unit of risk over the last 3 months. Ultragenyx exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Ultragenyx's Variance of 41.99, coefficient of variation of (1,591), and Risk Adjusted Performance of (0.04) to confirm the risk estimate we provide. The entity has a beta of 1.56, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ultragenyx will likely underperform. At this point, Ultragenyx has a negative expected return of -0.47%. Please make sure to validate Ultragenyx's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Ultragenyx performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.58 |
Modest predictability
Ultragenyx has modest predictability. Overlapping area represents the amount of predictability between Ultragenyx time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ultragenyx price movement. The serial correlation of 0.58 indicates that roughly 58.0% of current Ultragenyx price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.58 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 1.13 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ultragenyx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ultragenyx reported net income of (569.18 Million). This is 266.78% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 199.69% higher than that of the company.
Ultragenyx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ultragenyx's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ultragenyx could also be used in its relative valuation, which is a method of valuing Ultragenyx by comparing valuation metrics of similar companies.Ultragenyx is currently under evaluation in net income category among its peers.
Ultragenyx Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ultragenyx from analyzing Ultragenyx's financial statements. These drivers represent accounts that assess Ultragenyx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ultragenyx's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 5.7B | 3.2B | 3.5B | 3.8B | 3.4B | 2.4B | |
| Enterprise Value | 5.4B | 3.1B | 3.3B | 3.7B | 3.3B | 2.3B |
Ultragenyx ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ultragenyx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ultragenyx's managers, analysts, and investors.Environmental | Governance | Social |
Ultragenyx Institutional Holders
Institutional Holdings refers to the ownership stake in Ultragenyx that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Ultragenyx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ultragenyx's value.| Shares | Wellington Management Company Llp | 2025-06-30 | 1.9 M | Geode Capital Management, Llc | 2025-06-30 | 1.7 M | Rtw Investments, Llc | 2025-06-30 | 1.7 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.7 M | Alkeon Capital Management, Llc | 2025-06-30 | 1.7 M | Deutsche Bank Ag | 2025-06-30 | 1.7 M | Adage Capital Partners Gp Llc | 2025-06-30 | 1.5 M | Bnp Paribas Investment Partners Sa | 2025-06-30 | 1.5 M | Alyeska Investment Group, L.p. | 2025-06-30 | 1.4 M | Vanguard Group Inc | 2025-06-30 | 10.2 M | Blackrock Inc | 2025-06-30 | 6.3 M |
Ultragenyx Fundamentals
| Return On Equity | -3.13 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.92) % | ||||
| Operating Margin | (1.07) % | ||||
| Current Valuation | 1.88 B | ||||
| Shares Outstanding | 96.48 M | ||||
| Shares Owned By Insiders | 3.13 % | ||||
| Shares Owned By Institutions | 96.87 % | ||||
| Number Of Shares Shorted | 9.1 M | ||||
| Price To Earning | (6.90) X | ||||
| Price To Book | 247.70 X | ||||
| Price To Sales | 3.14 X | ||||
| Revenue | 673 M | ||||
| Gross Profit | (163.82 M) | ||||
| EBITDA | (535 M) | ||||
| Net Income | (569.18 M) | ||||
| Cash And Equivalents | 542.8 M | ||||
| Cash Per Share | 7.75 X | ||||
| Total Debt | 40.34 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 0.1 X | ||||
| Cash Flow From Operations | (414.19 M) | ||||
| Short Ratio | 2.77 X | ||||
| Earnings Per Share | (5.83) X | ||||
| Price To Earnings To Growth | (0.24) X | ||||
| Target Price | 61.84 | ||||
| Number Of Employees | 1.29 K | ||||
| Beta | 0.16 | ||||
| Market Capitalization | 1.98 B | ||||
| Total Asset | 1.5 B | ||||
| Retained Earnings | (3.96 B) | ||||
| Working Capital | 472.97 M | ||||
| Current Asset | 416.79 M | ||||
| Current Liabilities | 50.43 M | ||||
| Net Asset | 1.5 B |
About Ultragenyx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ultragenyx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultragenyx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultragenyx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:Check out For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Biotechnology sector continue expanding? Could Ultragenyx diversify its offerings? Factors like these will boost the valuation of Ultragenyx. Anticipated expansion of Ultragenyx directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ultragenyx data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (5.83) | Revenue Per Share | Quarterly Revenue Growth 0.147 | Return On Assets | Return On Equity |
Understanding Ultragenyx requires distinguishing between market price and book value, where the latter reflects Ultragenyx's accounting equity. The concept of intrinsic value - what Ultragenyx's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ultragenyx's price substantially above or below its fundamental value.
It's important to distinguish between Ultragenyx's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ultragenyx should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Ultragenyx's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.